Monday 15 May 2023

Monday 15 May




Opening/Welcome ANR meeting

09:15 - 10:15 Plenary session 1: Genetic defects and dependencies in neuroblastoma

Moderators: Matthias Fischer, Germany & Carol Thiele, United States


PS1.1 Spontaneous regression and differentiation in neuroblastoma lacking telomerase

Lisa Werr, Germany


PS1.2 TFIIIC and MYCN link the three-dimensional chromatin structure of promoters to transcription termination of stalled RNA polymerase II

Martin Eilers, Germany


PS1.3 Inactivating mutations of MKK7 in a subgroup of high-risk neuroblastoma

Anna-Maria Hellman, Germany


PS1.4 BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma

Kristopher Bosse, United States


10:15 - 10:45 Coffee break

10:45 - 11:35 Parallel session 1: Genetic defects and dependencies in neuroblastoma

Moderators: Meredith Irwin, Canada & Glenn Marshall, Australia


O1.1 ATRX alterations mediate an immunogenic phenotype and macrophage infiltration in neuroblastoma

Federica Lorenzi, UK


O1.2 Distinct molecular phenotypes and genetic dependencies within ATRX aberrant neuroblastoma tumors

Marlinde Van Den Boogaard, the Netherlands


O1.3 DNA Damage Repair Deficiency Enhances Neuroblastoma Progression and In vivo Sensitivity to PARP Inhibition in Zebrafish

Madeline Hayes, Canada


O1.4 ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation

Marcus Borenäs, Sweden

10:45 - 11:35 Parallel session 2: Treatment strategies for low risk NB

Moderators: Max van Noesel, the Netherlands & Barbara Hero, Germany


O2.1 Outcomes for patients aged 12-18 months with metastatic MYCN non-amplified neuroblastoma and unfavorable biologic features (‘Mixed Biology Toddlers’)

Thomas Cash, United States


O2.2 Short term motor outcomes for patients with spinal canal invasion in neuroblastoma – a SIOPEN prospective study

Shifra Ash, Israel


O2.3 MYCN amplification in INSS stage 1 tumors: is there a need for treatment?

Barbara Hero, Germany


O2.4 Polyclonal lymphoid expansion drives paraneoplastic autoimmunity in neuroblastoma. Associated with Opsoclonus Myoclonus Ataxia Syndrome (OMAS)

Miriam Rosenberg, Israel

11:35 - 11:50 Rapid Fire session 1A

Moderator: Jan Molenaar, the Netherlands


P023 Designing Novel Drug Combinations to Improve Sensitivity of ALK-Driven Neuroblastoma Cells to Lorlatinib

Smita Matkar, United States


P019 High-resolution analysis of structural genomic alterations in neuroblastoma by linked-read whole-genome sequencing

Christoph Bartenhagen, Germany


P022 Genetic predisposition to neuroblastoma results from a regulatory polymorphism promoting the adrenergic cell state in zebrafish and human

Nina Weichert-Leahey, United States


P018 he druggable target KAT2A forms a feedforward loop with MYCN to drive an oncogenic neuroblastoma transcriptional program

Zhihui Liu, United States


P021 The chromatin reader PHF6 interacts with RRM2 to control replication stress and DNA damage responses in neuroblastoma

Lisa Depestel, Belgium


P001 Copper chelation downregulates YTHDF2 RNA-binding protein causing growth inhibition and decreased MYCN expression

Jessica Bell, Australia


P020 Defining the landscape of circular RNAs in neuroblastoma unveils a global suppressive function of MYCN

Steffen Fuchs, Germany


P070 Clinically relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance

Adriana Mañas, Sweden


P075 Palbociclib releases the latent differentiation capacity of neuroblastoma cells

Kirsty Ferguson, UK


P074 Study of spatial and temporal epigenetic heterogeneity in high-risk neuroblastoma suggests role of H3K27me3-mediated repression

Charlotte Butterworth, France


11:50 - 13:15 Lunch

Poster viewing P001 - P191

13:15 - 14:00 Keynote Lecture 1

Moderator: Rogier Versteeg, the Netherlands


Studying melanoma evolution one cell at the time

Chris Marine, Belgium

Although melanoma is notorious for its high degree of heterogeneity and plasticity, the origin and magnitude of cell state diversity remains poorly understood. Equally, it is not known whether melanoma growth and metastatic dissemination and therapy resistance are supported by overlapping or distinct melanoma subpopulations. Leveraging single-cell and spatial transcriptomics, we established a high-resolution and spatially-resolved map of the drug-naïve melanoma ecosystem and a comprehensive view of the malignant transcriptomic landscape. Moreover, by combining mouse genetics, unbiased lineage tracing and quantitative modelling, we provide evidence of a hierarchical model of tumour growth that mirrors the cellular and molecular logic underlying embryonic neural crest cell fate specification and differentiation. Our findings indicate that tumorigenic competence is associated with a spatially localized perivascular niche environment, a phenotype acquired through a NOTCH3-dependent intercellular communication pathway established by endothelial cells. Consistent with a model in which only a fraction of melanoma cells is fated to fuel growth, temporal single-cell tracing of a population of melanoma cells harbouring a mesenchymal-like state revealed that these cells do not contribute to primary tumour growth but, instead, constitutes a pool of metastatic-initiating cells.

We next studied how targeted therapy and immune checkpoint blockade (ICB) remodel the entire melanoma ecosystem. We identified a series of melanoma cell states, and their underlying gene regulatory networks, that are either selected by and/or induced by the treatment to constitute a pool of relapsing-initiating cells. These studies demonstrate that the ability to support growth, metastasis and therapy resistance is limited to partly overlapping pools of melanoma subpopulations. The observation that these phenotypic competencies can be dynamically acquired upon exposure to specific niche signals warrant the development of therapeutic strategies that interfere with the cancer cell reprogramming activity of such microenvironmental cues.

14:00 - 15:00 Plenary session 2: Plasticity in neuroblastoma and normal development

Moderators: Susanne Schlisio, Sweden & Frank Westermann, Germany


PS2.1 Tracing the dynamics of neuroblastoma transcriptomic states across the metastatic progression with high depth single cell approaches

Céline Delloye-bourgeois, France


PS2.2 Spatial and single-cell transcriptomics characterize tumor heterogeneity and early stage tumors in mouse neuroblastoma models

Nour El Houda Djerir, France


PS2.3 Expansion of an early SOX2 positive cell population in germline ALK mutant iPSCs during in vitro differentiation towards sympathoadrenal progenitors

Stéphane Van Haver, Belgium


PS2.4 Identification, characterization and therapeutic targeting of chemotherapy resistant high-risk neuroblastoma persister cells

Liron Grossmann, Israel


15:00 - 15:30 Coffee break

15:30 - 16:20 Parallel Session 3: Plasticity in neuroblastoma and normal development

Moderators: Céline Delloye-Bourgeois, France & Isabel Janoueix-Lerosey, France


O3.1 Single-cell analysis of heterogeneity in a neuroblastoma relapse model in vivo

Ellen Westerhout, the Netherlands


O3.2 Epigenetically manifested regulatory networks in three major neuroblastoma subtypes

Kai-Oliver Henrich, Germany


O3.3 Single-cell clonal heterogeneity and cell-state analysis reveals genomic evolution and developmental cell-state transitions in neuroblastoma

Jörg Otte, Sweden


O3.4 Single-cell RNA sequencing identifies differences between paired samples of primary tumour and bone marrow metastasis

Caroline Hochheuser, the Netherlands

15:30 - 16:20 Parallel Session 4: 'Bioinformatics, clinical data and sample repositories

Moderators: Jan Koster, the Netherlands & Wendy London, United States


O4.1 Neuroblastoma develops in early fetal development and its evolutionary duration predicts outcome

Verena Körber, Germany


O4.2 SIOPEN BIOPORTAL: An international registry linked to a virtual biobank for patients with peripheral neuroblastic tumours

Priyanka Devi-marulkar, France


O4.3 Systematic review of studies identifying clinical and biological markers of poor survival in high-risk neuroblastoma patients at diagnosis: INRG-BORNEO project

Andrea Vilaplana Blanes, Spain


O4.4 Building a REDCap on FHIR Tool to Abstract Neuroblastoma Data from Electronic Health Records (EHRs): A Proof-of-Concept Study

Brian Furner, United States


Poster Session Group A

Posters with reference P1 until P110


Welcome reception

From 17:30 until 19:00 hrs.